- Home
- BCTX vs SCNX Comparison
BCTX vs SCNX Comparison
Compare BCTX & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- SCNX
- Stock Information
- Founded
- BCTX 2014
- SCNX 2010
- Country
- BCTX Canada
- SCNX United States
- Employees
- BCTX N/A
- SCNX N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- BCTX Health Care
- SCNX Health Care
- Exchange
- BCTX Nasdaq
- SCNX Nasdaq
- Market Cap
- BCTX 17.2M
- SCNX 14.0M
- IPO Year
- BCTX N/A
- SCNX 2020
- Fundamental
- Price
- BCTX $0.79
- SCNX $8.10
- Analyst Decision
- BCTX Strong Buy
- SCNX
- Analyst Count
- BCTX 1
- SCNX 0
- Target Price
- BCTX $15.00
- SCNX N/A
- AVG Volume (30 Days)
- BCTX 690.7K
- SCNX 18.2K
- Earning Date
- BCTX 12-12-2024
- SCNX 11-06-2024
- Dividend Yield
- BCTX N/A
- SCNX N/A
- EPS Growth
- BCTX N/A
- SCNX N/A
- EPS
- BCTX N/A
- SCNX 3.55
- Revenue
- BCTX N/A
- SCNX N/A
- Revenue This Year
- BCTX N/A
- SCNX $1,085.75
- Revenue Next Year
- BCTX N/A
- SCNX N/A
- P/E Ratio
- BCTX N/A
- SCNX $3.46
- Revenue Growth
- BCTX N/A
- SCNX 166.67
- 52 Week Low
- BCTX $0.46
- SCNX $3.69
- 52 Week High
- BCTX $5.97
- SCNX $44.56
- Technical
- Relative Strength Index (RSI)
- BCTX 55.70
- SCNX N/A
- Support Level
- BCTX $0.57
- SCNX N/A
- Resistance Level
- BCTX $0.74
- SCNX N/A
- Average True Range (ATR)
- BCTX 0.06
- SCNX 0.00
- MACD
- BCTX 0.00
- SCNX 0.00
- Stochastic Oscillator
- BCTX 88.08
- SCNX 0.00
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.